Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kaluza for Gallios Delivers Ease of Use, Analytical Power for Researchers

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
Beckman Coulter offers new software package for data acquisition in cytometry, for use across cell analysis applications.

Kaluza for Gallios software combines cutting edge data acquisition tools with remarkable ease of use to increase efficiency and performance in the cell characterization and analysis workflow of core research laboratories.

Researchers at all levels of experience can learn the system quickly using this next generation acquisition software for the Beckman Coulter Gallios cytometer.

Users maximize productivity and data output through novel functionalities, such as the ability to set up experimental protocols offline and a Gallios simulator, which facilitates instrument training without running live experiments.

The new software combines with Kaluza Analysis, a leading cytometry data analysis programme, and together the packages provide a total cytometry data management solution.

Kaluza for Gallios features a guided Windows-based drag-and-drop interface that is intuitive and facilitates easy creation of the right setup for accurate plot output. Visual management tools enable tracking of instrument function and experiment progress. Voltage and compensation can be quickly, accurately and intuitively changed.

The wizard function makes it easy to create compensation matrices, and a radial menu means minimal click-through while creating gates and accessing editing tools. Unlimited “undo” aids new users.

Gallios flow cytometers couple excellent sensitivity, resolution and dynamic range with high-speed data collection. Digital signal processing is accurate at high event rates over a range of fluorescence intensities.

The systems house up to three solid-state lasers, with red and blue standard and violet or yellow available as an option, and have easily interchangeable optical filters for detection of a variety of dyes and wavelengths.

An innovative forward-scatter detector provides up to three measurements of cell size and visualization of particles down to 0.404 µm in diameter, and fluorescent detectors enable concurrent reading of up to 10 colours.

“Researchers will use the time savings, flexibility and analytical power of Kaluza for Gallios to further their experiments and make lab time more productive,” said Sharlene Wright, senior manager at Beckman Coulter Flow Cytometry. “Offering a version of the software that is dedicated to enhancing the performance of the market leading Kaluza Analysis and Gallios will help researchers achieve greater productivity. It continues the vision of Kaluza platform development - implementing this powerful analytical product to simplify complex flow cytometry data acquisition.”

Kaluza for Gallios flow cytometry analysis software is for research use only and is provided on a Windows 7 (64-bit) operating system. Examples of Kaluza’s unique data analysis tools can be viewed at www.kaluzasoftware.com, and a fully functional trial version can be ordered. Offline software for Kaluza for Gallios and the Gallios simulator is available at www.kaluzasoftware.com.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Beckman To Acquire Cytometer Developer Xitogen
Acquisition will broaden product offering, providing an Asian operations centre.
Wednesday, April 23, 2014
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!